Rapid uptake of biosimilars expected in US
Adoption of biosimilars is expected to be rapid in the US - at least in the field of nephrology.
Adoption of biosimilars is expected to be rapid in the US - at least in the field of nephrology.
A survey of nephrologists, conducted by BioTrends Research Group, found that more than 60 per cent plan to start prescribing the biosimilar epoetin alfa within 12 months of the drug's launch.
Comparable rates of uptake have already been recorded in Germany, where nephrologists have embraced the biosimilar.
Dr Andrew Merron, director of the Biosimilars Advisory Service, revealed that US nephrologists expect to prescribe the biosimilar darbepoetin alfa to a greater proportion of eligible patients than their counterparts in France and Germany.
"This suggests that biosimilar erythropoiesis-stimulating agents (ESAs) will experience deeper, as well as more rapid, market penetration in the United States than we've seen in Europe as a whole," he suggested.
However, adoption of biosimilar insulins by endocrinologists is not expected to be as rapid, with their market share forecast to reach just eight per cent by 2021, compared with 36 per cent for ESAs across the US, Europe and Japan.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.